Healthcare / Medical DevicesShanghai
$20.22
-1.98 (-8.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $58.1M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
N/A
•EV/EBITDA
50.9x
↑ROE
-1.0%
↓Gross Margin
64.2%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-62.3%
FCF CAGR
-49.7%
FCF margin
52.0%
FCF / Net income
-1.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $124.8M · net income $-34.3M · FCF $64.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $124.8M | $124.8M | $178.7M | $274.3M | $2.33B |
| Net Income | $-34.3M | $-34.3M | $-127.5M | $-136.9M | $760.3M |
| EBITDA | $27.4M | $27.4M | $-81.8M | $-89.6M | $966.0M |
| EPS | -0.19 | -0.19 | -0.67 | -0.71 | 3.93 |
| Gross Margin | 64.2% | 64.2% | 60.9% | 65.1% | 51.6% |
| Operating Margin | -76.8% | -76.8% | -55.5% | -16.6% | 34.8% |
| Net Margin | -27.5% | -27.5% | -71.3% | -49.9% | 32.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 25.19 | 25.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $64.9M | $64.9M | $58.1M | $-163.0M | $510.4M |
| Returns | |||||
| ROE | -1.0% | -1.0% | -3.5% | -3.6% | 18.1% |
| Valuation | |||||
| P/E | — | — | — | — | 8.60 |
| EV/EBITDA | 50.86 | 50.86 | — | — | 3.52 |
| P/B | 1.09 | 1.09 | 0.82 | 1.03 | 1.56 |
| Growth & Yield | |||||
| Revenue Growth | -30.1% | -30.1% | -34.9% | -88.2% | — |
| EPS Growth | 71.6% | 71.6% | 5.6% | -118.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.67 → -0.19
Residual
+18.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.